BACKGROUND: A recently identified germline mutation G84E in HOXB13 was shown to increase the risk of prostate cancer. In a family-based analysis by The International Consortium for Prostate Cancer Genetics (ICPCG), the G84E mutation was most prevalent in families from the Nordic countries of Finland (22.4%) and Sweden (8.2%). METHODS: To further investigate the importance of G84E in the Finns, we determined its frequency in more than 4,000 prostate cancer cases and 5,000 controls. In addition, 986 breast cancer and 442 colorectal cancer (CRC) cases were studied. Genotyping was conducted using TaqMan, MassARRAY iPLEX, and sequencing. Statistical analyses were conducted using Fisher exact test, and overall survival was analyzed using Cox modeling. RESULTS: The frequency of the G84E mutation was significantly higher among patients with prostate cancer and highest among patients with a family history of the disease, hereditary prostate cancer [8.4% vs. 1.0% in controls; OR 8.8; 95% confidence interval (CI), 4.9-15.7]. The mutation contributed significantly to younger age (≤55 years) at onset and high prostate-specific antigen (PSA; ≥20 ng/mL) at diagnosis. An association with increased prostate cancer risk in patients with prior benign prostate hyperplasia (BPH) diagnosis was also revealed. No statistically significant evidence for a contribution in CRC risk was detected, but a suggestive role for the mutation was observed in familial BRCA1/2-negative breast cancer. CONCLUSIONS: These findings confirm an increased cancer risk associated with the G84E mutation in the Finnish population, particularly for early-onset prostate cancer and cases with substantially elevated PSA. IMPACT: This study confirms the overall importance of the HOXB13 G84E mutation in prostate cancer susceptibility.
RCT Entities:
BACKGROUND: A recently identified germline mutation G84E in HOXB13 was shown to increase the risk of prostate cancer. In a family-based analysis by The International Consortium for Prostate Cancer Genetics (ICPCG), the G84E mutation was most prevalent in families from the Nordic countries of Finland (22.4%) and Sweden (8.2%). METHODS: To further investigate the importance of G84E in the Finns, we determined its frequency in more than 4,000 prostate cancer cases and 5,000 controls. In addition, 986 breast cancer and 442 colorectal cancer (CRC) cases were studied. Genotyping was conducted using TaqMan, MassARRAY iPLEX, and sequencing. Statistical analyses were conducted using Fisher exact test, and overall survival was analyzed using Cox modeling. RESULTS: The frequency of the G84E mutation was significantly higher among patients with prostate cancer and highest among patients with a family history of the disease, hereditary prostate cancer [8.4% vs. 1.0% in controls; OR 8.8; 95% confidence interval (CI), 4.9-15.7]. The mutation contributed significantly to younger age (≤55 years) at onset and high prostate-specific antigen (PSA; ≥20 ng/mL) at diagnosis. An association with increased prostate cancer risk in patients with prior benign prostate hyperplasia (BPH) diagnosis was also revealed. No statistically significant evidence for a contribution in CRC risk was detected, but a suggestive role for the mutation was observed in familial BRCA1/2-negative breast cancer. CONCLUSIONS: These findings confirm an increased cancer risk associated with the G84E mutation in the Finnish population, particularly for early-onset prostate cancer and cases with substantially elevated PSA. IMPACT: This study confirms the overall importance of the HOXB13G84E mutation in prostate cancer susceptibility.
Authors: Virpi H Laitinen; Tommi Rantapero; Daniel Fischer; Elisa M Vuorinen; Teuvo L J Tammela; Tiina Wahlfors; Johanna Schleutker Journal: Int J Cancer Date: 2014-11-08 Impact factor: 7.396
Authors: Jennifer L Beebe-Dimmer; Matthew Hathcock; Cecilia Yee; Linda A Okoth; Charles M Ewing; William B Isaacs; Kathleen A Cooney; Stephen N Thibodeau Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-06-24 Impact factor: 4.254
Authors: Veda N Giri; Karen E Knudsen; William K Kelly; Wassim Abida; Gerald L Andriole; Chris H Bangma; Justin E Bekelman; Mitchell C Benson; Amie Blanco; Arthur Burnett; William J Catalona; Kathleen A Cooney; Matthew Cooperberg; David E Crawford; Robert B Den; Adam P Dicker; Scott Eggener; Neil Fleshner; Matthew L Freedman; Freddie C Hamdy; Jean Hoffman-Censits; Mark D Hurwitz; Colette Hyatt; William B Isaacs; Christopher J Kane; Philip Kantoff; R Jeffrey Karnes; Lawrence I Karsh; Eric A Klein; Daniel W Lin; Kevin R Loughlin; Grace Lu-Yao; S Bruce Malkowicz; Mark J Mann; James R Mark; Peter A McCue; Martin M Miner; Todd Morgan; Judd W Moul; Ronald E Myers; Sarah M Nielsen; Elias Obeid; Christian P Pavlovich; Stephen C Peiper; David F Penson; Daniel Petrylak; Curtis A Pettaway; Robert Pilarski; Peter A Pinto; Wendy Poage; Ganesh V Raj; Timothy R Rebbeck; Mark E Robson; Matt T Rosenberg; Howard Sandler; Oliver Sartor; Edward Schaeffer; Gordon F Schwartz; Mark S Shahin; Neal D Shore; Brian Shuch; Howard R Soule; Scott A Tomlins; Edouard J Trabulsi; Robert Uzzo; Donald J Vander Griend; Patrick C Walsh; Carol J Weil; Richard Wender; Leonard G Gomella Journal: J Clin Oncol Date: 2017-12-13 Impact factor: 44.544
Authors: Sofia Maia; Marta Cardoso; Paula Paulo; Manuela Pinheiro; Pedro Pinto; Catarina Santos; Carla Pinto; Ana Peixoto; Rui Henrique; Manuel R Teixeira Journal: Fam Cancer Date: 2016-01 Impact factor: 2.375